Header updated on 24th April 2008

Market has been looking for an announcement re a licensing deal for Cetilistat, the obesity drug; instead it has been hit with the withdrawal of Renzapride, colonitis drug, following an unauspicious performance at Phase III. Folloiwng has been edited to reflect the situation

Alizyme is a speciality biopharmaceutical company that has been developing product categories for inflammatory gastrointestinal disorders, obesity and supportive cancer care . It is currently trading at a five year low of around 27p with a market cap. of around 60m. Prudential owned a near 20% stake (reduced in sale today?) There was good institutional taku-up of a placing in March rasing 10m at 50p; no wonder there has been "angry" selling. The directors hold 3.34million shares or about 1.7% of the equity (of which Tim McCarthy, CEO has 1.1million); thus, after some 10 years of development effort, they must be comletely focused on the success of the company and multiplying the value of their holdings (but with real doubts about their marketing competence). Alizyme had previously raised capital sums in the past three years at around 70p and 100p so it was somewhat surprising to see the share fall through its 70p support level. Clearly one reason is the current disaffection with the biopharm. market. Another has to be disappointment for the failure of the CEO, Tim McCarthy, to deliver on his expectation that 2007 would be a transformative year. The key question is whether 2008 will be that year and when is it likely to happen? The following points are relevant:

1. Alizyme did sign one deal in late-2007: with Prometheus Labs (U.S.) for the Colal-Pred, at a potential market of $250m, the smallest potential of their four products. Prometheus pay $2.5m up-front with a total of $15m payable upon future development milestones. They are responsible for all US development costs and will pay Alizyme undisclosed royalty rates which will increase with net sales. The deal was followed by a Japanese licensing agreement (which also gave Alizymen access to additional potential drug candidates).

2. This perhaps sets a precedent for subsequent deals for their other products. Cetistat (obesity) has an estimated potential of $1 billion p.a. sales and ATL-104 (mucositis) has a potential of $500m sales. The U.S. FDA has encouraged AZM to also launch a Phase III exercise for Cetistat for all diabetes sufferer because of positive II results for diabetes sufferers who also suffer from obesity.

3. Whilst the development programmes for the other drugs are on-going and appear to be satisfactorily funded from present resources, this is not the case for Cetilistat. The "Product and Company Update statement" (7th Jan 2008) says that 'the Phase III development programme is now ready to commence following the conclusion of a commercial deal'. So, perhaps for the first time, the development programme would be delayed if there was not a funding deal in either the U.S. or Europe. The reason for the sp shooting to nearly 200p in 2004 was the signing of a deal with Takada of Japan for some $50M development funding.

In response to a question at the Conference to report the Renzapride fiasco, McCarthy seemed pleased that there were six potential bidders for Cetilistat; however, that implies any announcement is some time away. When it comes, however, taking a line from the Takada and Prometheus deals it would seem likely that there would be of the order of $100m funding to support development. Of course, the major cash flow will be from licensing of actual sales. The analysts do their own discounted cash flow exercises; those seen tend to dwarf current valuations of the company.

There is not a strong argument for jumping in unless and until the sp establishes a baseline. Given the peaks in the sp, the time will probably come when there will be a very significant jump. An alternative scenario, is that management continue to rpove their level of incompetence and a buy-our results. Clearly the strength of the company is in their biochemists.

Eric

The update required
UK smallcap opening - Alizyme better after successful trial results
AFX


LONDON (AFX) - Solid progress was logged in Alizyme, 13-1/4 pence better at 179-3/4, after the company said preliminary results of its Phase IIa clinical trial to evaluate ATL-104 for the treatment of mucositis -- which demonstrated positive responses in patients -- have been successful.

A statement from the company said ATL-104 'did not appreciably alter the adverse event profile attributed to the chemotherapy regimens'.

newsdesk@afxnews.com

fjb/vjt

thank you Eric-delighted so far!

Pleased to have a satisfied customer, moneyplus, and I'm sure Ruthie will also be a happy girl. What I really like about AZM is their professionalism: they have been going nearly 10 years now on the 4 potential drugs they acquired; every step is well planned and each delivery has been achieved. Thus confidence is high in success with all four. ATL-104 has a smaller market that cetilistat but still $500m;it is also behind the other 3; the next phase will be much larger and no doubt run into 2007. As I understand it, they will obtain a licensing partner befor long for Cetilistat but could well run with the other three off the back of that funding. The size of that deal could justify the sp on its own so that the share has a long way yet to run.

Eric

ive been in and out eric, back in at the mo. already made one very handsome profit, now looking to make another. good luck to all.

Still here holding AZM Eric, one of my long term buy and holds.

Enjoying the recent move North immensely.

all the best.

capa

Pleased to see you're still on board, Kivver and capa. I'm looking to Q2 for the big announcemnet re licensing with a run up to new ground. Possibly a resistance level around the current level but I think institutional investors will hold so new money could drive sp through the resistance.
Eric

Eric
Yes sir very happy. Managed to keep most of my profits from SEO, got into CHP at 6.9!! and my ISA fund has taken in AZM as a long term hold. So apart from an unlucky turn on ASC via a CFD the last year or so has been good to me...even my funds are up way more than deposit returns. I am still learning but must thank you and several other good posters for all the research that's done which I wouldn't have the time to do.
Regards Ruthie

Thanks, Ruthie. A really good thing about AZM is that the research facts are on the table due to the pharma. trials process. I'm fascinated by the extent of the positive market reaction to the mucositis drug; this compares with the muted reaction to last year's progress. OK, the drug must be worth 50M+ at this stage of development, which is some 30p on the sp. But it confirms that there is a pent-up demand, much presumably from institutions. There is a historical resistance level at around 190p, two years ago. But we are two years of on-schedule progress further forward and the momentum could take it through to new ground - there was a spike to about 220p but I think that was a defensive MM mark-up, sensing a cetilistat licensing deal, which didn't materialise.
Regards Eric

Think I should probably update the heading piece with an update on the products, wherre they are and what the perceived potential is. Will try to do it at the weekend. I see the aim is to help newcomers evaluating the stock. I think if one trawls through the records you can quantify the earnings potential three years down the line.
Eric

that would be great Eric, liking this one a lot. (but not falling in love, your not allowed to that!,lol) ps dont forget to have a look at corus, creeping up slowly but nicely. great for the long term.

Suspect AZM and Corus have in common that they are going through a period of re-rating by the market, although I prefer the emerging company. AZM is a long-term play in the sense that it'll be around 2008 that its drugs are going commercial. So it is easier to assess the value in 2008, possibly 2billion. But how will the moement be phased form A to B. My point is that the level of uncertainty has dropped substantially with the completion of Phase 2B for cetilistat in the US. Now, news of the support players is treated very positively. The big step will be the licensing deal for the former, but the sp should continue to move in the meantime. I am looking for 250p then a jump to 300p on the deal; may be too cautious!

Eric

Another very good day-looking forward to next week. have a good weekend all.

Well after watching and waiting for a little while I have now taken the plunge with AZM and have joined the party.

very disappointed to seethe directors selling, willl it have an impact.???

http://www.companyannouncements.co.uk/cgi-bin/articles/200603101139446172Z.html

Yes!

thanks!

Got back in after the market closed on Friday to see the fall in share price. Thought at first it was a reaction to the results which seemed strange because there was no reason why one should have expected anything different. As Fred knew, the announcement of director sales would have a knock-on effect and so it proved with a 7% fall. Really, there was nothing sinister. The price has risen during the close period and it is therefore the first opportunity for directors to cash in on the rise in sp. You could also include that news on a licensing deal is not imminent. On the positive side, you can probably conclude that it is not the dierctor's plans to raise the additional funding needed this year from the market.

It is also clear from the results statements that they will do licensing deals: this is the 'pivotal year' for that purpose. It really is an amazing performance to get all their four drugs successfully through to late-stage development. There must be a significant jumponce we can quantify licensing deal(s) but it amy need some patience.

Eric

I think there is one other problem and that is Cash Burn. I am not sure whwt the cash in hand is at present or whether there will be futher cash raising before sufficient cash flow to come costs.

I will have a look later. I am happy to get out with a good profit, but may buy again later after the dust has settled.

Fred, the cash position is strong with cash at the year end at 30.8m. Don't know the ratio of phase 2b to phase 3, but suspect it is not less than 1 to 3. In other words, and I think this is confirmed by company comment, the present cash may see them through the two smaller drugs but certainly not cetilistat. My feel is that they will not acheive a licensing deal before June, but that they will not return to the amrket for more capital. I would see that as a credibility issue havein stated that they are looking for the licensing deal. I remain somewhat surprised at the amount of director cashing in of options which suggests that the size of such deals may be less than I for one have anticipated. Any views? I have reduced my holding, via cfd, substantially, really for defensive reasons; anyway its banking a decent profit. I could see more selling as the weeklies report the director disposals.

hope you had a little dabble in corus eric. glad i stayed in azm when everyone else was bailing out.